Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868751 · ClinicalTrials.gov registry record · NA
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis
A NA study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00868751 is a NA study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT00868751, a NA study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.
Interventions
- BIOLOGICAL tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868751
The ClinicalTrials.gov registry entry for NCT00868751 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tocilizumab is the first listed.
NCT00868751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868751 about?
NCT00868751 is a clinical study titled "Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis". The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.
What is the current status of trial NCT00868751?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00868751?
The interventions under investigation include: tocilizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00868751?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.